Rinatabart Sesutecan (RINA-S) For Patients With Platinum-Resistant Ovarian Cancer: First Efficacy and Safety Results From the Phase 2 Cohort of the RAINFOL-01 Study
Document Type
Conference Proceeding
Publication Date
10-2026
Publication Title
Interanational Journal of Gynecological Cancer
Abstract
Introduction: Rinatabart sesutecan (Rina-S) is an investigational FRα-directed ADC with a topoisomerase I inhibitor payload and a hydrophilic protease-cleavable linker. Dose optimization identified 120 mg/m2 as the RP2D for Rina-S in platinum-resistant ovarian cancer (PROC). Here, we report single-arm phase 2 results from RAINFOL-01™ (NCT05579366) evaluating Rina-S 120 mg/m2 Q3W monotherapy in patients with PROC. Methods: Patients had metastatic or unresectable PROC and received 1-3 prior lines of therapy (pLOT) or up to 4 pLOT if mirvetuximab (MIRV) was the most recent pLOT for patients with FRα ≥75% expression. Enrollment was not restricted by FRα expression level. Primary endpoint was ORR. Secondary endpoints included DOR, PFS, OS, and safety. Preliminary Data or Expected Results: Overall, 109 patients were treated (median follow-up, 13.6 months). Over half (53%) of patients received 3 or 4 pLOT. All patients had received prior bevacizumab and taxane; 33% had received prior MIRV. The investigator-assessed confirmed ORR was 45.9% (95% CI, 36.3-55.7), including 5 CRs; DCR was 94.5% (95% CI, 88.4-98.0). Median DOR was 12.1 months (95% CI, 6.5-15.4) with 42% of responses ongoing at data cutoff, including all CRs. Median PFS was 9.5 months (95% CI, 7.6-11.3). Grade ≥3 treatment-emergent adverse events (TEAEs) were primarily neutropenia (33.9%), anemia (30.3%), or thrombocytopenia (23.9%). No fatal TEAEs occurred. TEAEs led to Rina-S discontinuation in 7 (6.4%) patients. Significance and Impact: Rina-S 120 mg/m2 Q3W led to substantial and durable antitumor activity, translating into meaningful PFS, with a tolerable safety profile in a broad population of patients with PROC who have an unmet need for effective new treatment options.
Volume
36
Issue
10 Suppl 1
First Page
4
Last Page
4
Recommended Citation
Lee E, Konecny G, Pepin J, Yeku O, Shahin MS, Winer I, et al. Rinatabart sesutecan (Rina-S) for patients with platinum-resistant ovarian cancer: first efficacy and safety results from the phase 2 cohort of the RAINFOL-01 study. Int J Gynecol Cancer. 2026 Oct;36(10 Suppl 1):4. doi: 10.1016/j.ijgc.2026.105619
DOI
10.1016/j.ijgc.2026.105619
Comments
International Gynecological Cancer Society (IGCS) 2026 Annual Global Meeting, October 1-3, 2026, Montreal, Canada